Article

Uncontrollable Urges to Gamble, Have Sex Linked to Antipsychotic Drug

Compulsive behavior – to gamble, binge eat, shop, and have sex – is linked to the antipsychotic drug aripiprazole.

The US Food and Drug Administration (FDA) is red-flagging aripiprazole (Abilify, Abilify Maintena, Aristada, as well as generics) as a cause of compulsive and uncontrollable behavior.

Aripiprazole was approved in late November 2002 to treat mental disorders such as schizophrenia, bipolar disorder, Tourette’s disorder, and irritability stemming from autistic disorder. Some of the most common side effects of the drug are nausea, headache, dizziness, insomnia, and anxiety. However, a FDA statement released on May 3 is warning potential impulse-control problems.

A total of 167 patients in the US have reported compulsive or uncontrollable urges to gamble, binge eat, shop, or have sex while on aripiprazole — the most common being to gamble with 164 cases. These people have since discontinued the medication.

  • MD Magazine is on Facebook, Twitter, Instagram, and LinkedIn!

“Healthcare professionals should make patients and caregivers aware of the risk of these uncontrollable urges when prescribing aripiprazole,” the report said, “and specifically ask patients about any new or increasing urges while they are being treated aripiprazole.”

These impulse-control issues are rare, officials say, but have the potential to lead to harmful outcomes. As a result, the FDA is requiring that these uncontrollable problems be added to the warning labels.

Sign up for MD Magazine’s trending & breaking news >>> here.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.